natgillin/translations-raw huggingface dataset:
Each pack contains 1 glass pre-filled syringe with an attached stainless steel needle and needle cap.
Ena škatla vsebuje 1 stekleno napolnjeno injekcijsko brizgo s pričvrščeno iglo iz nerjavečega jekla in pokrovčkom igle.
Special populations Renal impairment No dose change is recommended in patients with renal impairment, including those with end-stage renal disease.
Pri bolnikih z okvarjenim delovanjem ledvic, vključno z bolniki z boleznijo ledvic v zadnjem stadiju, se sprememba odmerka ne priporoča.
Common
Splošno
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
4.1 Terapevtske indikacije Skrajšanje trajanja nevtropenije in v primeru nastanka febrilne nevtropenije pri odraslih bolnikih, ki prejemajo citotoksično kemoterapijo za maligne tvorbe (z izjemo kronične mieloične levkemije in mielodisplastičnih sindromov).
The pharmacokinetics of pegfilgrastim were studied in 37 paediatric patients with sarcoma, who received
Farmakokinetiko pegfilgrastima so raziskali pri 37 pediatričnih bolnikih s sarkomom, ki so po dokončanju kemoterapije z VAdriaC/IE prejeli 100 µg/kg pegfilgrastima.
Studies in rats indicated that reproductive performance, fertility, oestrous cycling, days between pairing and coitus, and intrauterine survival were unaffected by pegfilgrastim given subcutaneously.
Študije, opravljene na podganah, so pokazale, da subkutano dovajanje pegfilgrastima ne vpliva na sposobnosti razmnoževanja, plodnost, pojatvene cikle, dni med seznanjanjem in parjenjem ter preživetje v maternici.
Clear, colourless solution for injection.
raztopina za injiciranje Bistra, brezbarvna raztopina za injiciranje.
Alvogen Romania SRL 44B, Theodor Pallady Blvd. 3rd district, 032266
44B, Theodor Pallady Blvd.
Keep the syringe and sharps disposal container out of sight and reach of children.
Brizgo in vsebnik za ostre odpadke shranjujte nedosegljivo otrokom.
• Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported rarely in cancer patients and healthy donors.
• Pri bolnikih z rakom in zdravih darovalcih so redko poročali o vnetju aorte (velike krvne žile, po kateri teče kri iz srca v telo).
Sæmundargötu 15-19, 101 Reykjavík, Ísland Tel: +354 522 2900
Sæmundargötu 15-19, 101 Reykjavík, Ísland
Grasustek contains the active substance pegfilgrastim.
Zdravilo Grasustek vsebuje učinkovino pegfilgrastim.
What Grasustek looks like and contents of the pack
Izgled zdravila Grasustek in vsebina pakiranja
Sickle cell crises have been associated with the use of pegfilgrastim in patients with sickle cell trait or sickle cell disease (see section 4.8).
Pri bolnikih s srpastimi celicami ali srpastocelično anemijo je bila uporaba pegfilgrastima povezana s srpastocelično krizo (glejte poglavje 4.8).
Sodium acetate * Sorbitol (E420) Polysorbate 20
sorbitol (E420)
years) had a higher mean exposure to pegfilgrastim (AUC) (± Standard Deviation) (47.9 ± 22.5 μg·hr/ml) than older children aged 6-11 years and 12-21 years (22.0 ± 13.1 μg·hr/ml and 29.3 ± 23.2 μg·hr/ml, respectively) (see section 5.1).
(47,9 ± 22,5 µg h/ml) kot pri otrocih, starih od 6-11 let (22,0 ± 13,1 µg·h/ml) in od 12-21 let (29,3 ± 23,2 µg h/ml) (glejte poglavje 5.1).
Grasustek contains sorbitol (E420) and sodium
Zdravilo Grasustek vsebuje sorbitol (E420) in natrij
Do not try to inject yourself if you have not been trained.
Če vas samoinjiciranja še niso naučili, si injekcij ne poskušajte dajati sami.
Allow the pre-filled syringe to reach room temperature before injecting.
Pred injiciranjem mora napolnjena injekcijska brizga doseči sobno temperaturo.
Warning/Precaution: DO NOT lift the product by the plunger or needle cover.
Opozorilo/previdnostni ukrep: Izdelka NE DRŽITE za bat ali za pokrovček igle.
On a clean, well-lit work surface, place the new pre-filled syringe and the other supplies.
Novo napolnjeno injekcijsko brizgo in druge pripomočke položite na čisto, dobro osvetljeno delovno površino.
Isolated cases of sickle cell crises have been reported in patients with sickle cell trait or sickle cell disease (uncommon in sickle cell patients) (see section 4.4).
Pri bolnikih s srpastimi celicami ali s srpastocelično anemijo so v posameznih primerih poročali o srpastocelični krizi (občasno pri bolnikih s srpastocelično anemijo) (glejte poglavje 4.4).
Once a syringe has been removed from the refrigerator and has reached room temperature (not above 30 °C) it must either be used within 3 days or disposed of.
Ko injekcijsko brizgo vzamete iz hladilnika in le-ta doseže sobno temperaturo (pod 30 °C), jo morate v
Remove the pre-filled syringe from blister as shown.
Napolnjeno injekcijsko brizgo vzemite z ovitka tako, kot kaže slika.
• coughing up blood (haemoptysis)
• izkašljevanje krvi (hemoptiza).
A higher frequency of serious adverse reactions in younger children aged 0-5 years (92 %) has been observed compared to older children aged 6-11 and 12-21 years respectively (80 % and 67 %) and adults.
Pri mlajših otrocih, starih od 0-5 let, so ugotovili večjo pogostnost resnih neželenih učinkov (92 %) kot pri starejših otrocih, starih od 6-11 let ter od 12-21 let (80 % oziroma
Hypersensitivity-type reactions, including skin rash, urticaria, angioedema, dyspnoea, erythaema, flushing, and hypotension occurred on initial or subsequent treatment with pegfilgrastim (uncommon [≥
Med začetnim ali nadaljnjim zdravljenjem s pegfilgrastimom so se pojavile reakcije preobčutljivostne vrste, vključno z izpuščajem na koži, urtikarijo, angioedemom, dispnejo, eritemom, zardevanjem in hipotenzijo (občasno [≥1/1.000 do <1/100]).
OTHER SPECIAL WARNING(S), IF NECESSARY
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Izogibajte se močnemu stresanju.
STATEMENT OF ACTIVE SUBSTANCE(S)
FARMACEVTSKI PODATKI Seznam pomožnih snovi natrijev acetat *
Uncommon side effects (may affect up to 1 in 100 people)
Občasni neželeni učinki (pojavijo se lahko pri največ 1 od 100 oseb):
Rare side effects (may affect up to 1 in 1,000)
Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 oseb):
In a phase II (n = 37) multicentre, randomised, open-label study of paediatric sarcoma patients receiving
V multicentrični, randomizirani, odprti študiji II.
Thrombocytopenia Leukocytosis1
Bolezni krvi in limfatičnega sistema trombocitopenija1; levkocitoza1
Hypersensitivity, including anaphylactic reactions, occurring on initial or subsequent treatment have been reported in patients treated with pegfilgrastim.
Med začetnim ali nadaljnjim zdravljenjem s pegfilgrastimom je bila opisana preobčutljivost, vključno z anafilaktičnimi reakcijami.
• are planning to have a baby
• načrtujete zanositev.
A small (n = 83), Phase II, randomised, double-blind study in patients receiving chemotherapy for de novo acute myeloid leukaemia compared pegfilgrastim (single dose of 6 mg) with filgrastim, administered during induction chemotherapy.
faze pri bolnikih, ki so prejemali kemoterapijo zaradi de novo akutne mieloične levkemije, je primerjala pegfilgrastim (enkraten 6-miligramski odmerek) s filgrastimom ob aplikaciji med indukcijsko kemoterapijo.
The entire dose has to be administered to trigger the guard.
Za sprostitev varnostnega ščitnika morate injicirati celotni odmerek.
Uncommon elevations in liver function tests (LFTs) for ALT (alanine aminotransferase) or AST (aspartate aminotransferase), have been observed in patients after receiving pegfilgrastim following cytotoxic chemotherapy.
Občasno so se bolnikom, ki so po citotoksični kemoterapiji prejeli pegfilgrastim, pojavila zvišanja jetrnih funkcijskih testov (LFT) za ALT (alanin-aminotransferaze) ali AST (aspartat-aminotransferaze).
Grasustek 6 mg solution for injection in pre-filled syringe
Grasustek 6 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
Pulmonary adverse reactions (interstitial pneumonia, pulmonary oedema, pulmonary infiltrates and pulmonary fibrosis) Haemoptysis
Bolezni dihal, prsnega koša in mediastinalnega prostora sindrom akutne dihalne stiske pljučni neželeni učinki (intesticijska pljučnica, pljučni edem, pljučni infiltrati in pljučna fibroza) hemoptiza pljučna hemoragija
Unless your doctor directs you otherwise, you must stop breast-feeding if you use Grasustek.
Če uporabljate zdravilo Grasustek, morate prenehati dojiti, razen če vam zdravnik ne naroči drugače.
The injections should be given into the thigh, abdomen or upper arm. 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1. 4.4 Posebna opozorila in previdnostni ukrepi
Uncommonly, cases have resulted in respiratory failure or ARDS, which may be fatal (see section 4.4).
ARDS, ki sta lahko smrtno nevarna (glejte poglavje 4.4).
(VAdriaC/IE) chemotherapy, a longer duration of severe neutropenia (neutrophils < 0.5 x 109) was observed in younger children aged 0-5 years (8.9 days) compared to older children aged 6-11 years and 12-21 years (6 days and 3.7 days, respectively) and adults.
faze pri pediatričnih bolnikih s sarkomom (n = 37), ki so dobili 100 µg/kg pegfilgrastima po 1. ciklusu kemoterapije z vinkristinom, doksorubicinom in ciklofosfamidom (VAdriaC/IE), so pri mlajših otrocih, starih od 0-5 let, ugotovili dolgotrajnejšo hudo nevtropenijo (nevtrofilci < 0,5 × 109) (8,9 dneva) kot pri starejših otrocih, starih od 6-11 let (6 dni) in od 12-21 let (3,7 dneva), in pri odraslih.
Grasustek 6 mg solution for injection in a pre-filled syringe pegfilgrastim
Grasustek 6 mg raztopina za injiciranje v napolnjeni injekcijski brizgi pegfilgrastim
Each pre-filled syringe contains 6 mg of pegfilgrastim in 0.6 ml (10 mg/ml) solution for injection.
Ena napolnjena injekcijska brizga vsebuje 6 mg pegfilgrastima v 0,6 ml (10 mg/ml) raztopine za injiciranje.
The needle has flexible, rigid needle shield.
Igla je zaščitena z upogljivim trdnim ščitnikom igle.
There were no adverse effects observed in offspring from pregnant rats given pegfilgrastim subcutaneously, but in rabbits pegfilgrastim has been shown to cause embryo/foetal toxicity (embryo loss) at cumulative doses approximately 4 times the recommended human dose, which were not seen when pregnant rabbits were exposed to the recommended human dose.
Pri potomcih brejih podgan, ki so jim subkutano dali pegfilgrastim, niso opazili neželenih učinkov, pri kuncih pa so pokazali, da pegfilgrastim v kumulativnih odmerkih, ki znašajo približno 4-kratni odmerek,
Uncommon events of cutaneous vasculitis have been reported in patients treated with pegfilgrastim.
Občasno so pri bolnikih, ki so jih zdravili s pegfilgrastimom, poročali o dogodkih kožnega vaskulitisa.
Pulmonary adverse reactions, in particular interstitial pneumonia, have been reported after G-CSF administration.
Po dajanju G-CSF so poročali o neželenih učinkih na pljučih, zlasti o intersticijski pljučnici.
Water for injections
polisorbat 20 voda za injekcije
Skin and subcutaneous tissue disorders
Bolezni prebavil navzea1 Bolezni kože in podkožja
Glomerulonephritis has been reported in patients receiving filgrastim and pegfilgrastim.
Pri bolnikih, ki so prejemali filgrastim in pegfilgrastim, so poročali o primerih glomerulonefritisa.
USE OF THE MEDICINAL PRODUCT
IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR BLISTERED SYRINGE
PODATKI NA ZUNANJI OVOJNINI ŠKATLA ZA BRIZGO V PRETISNEM OMOTU
Aortitis has been reported after G-CSF administration in healthy subjects and in cancer patients.
Po dajanju G-CSF zdravim osebam in onkološkim bolnikom so poročali o aortitisu.
PHARMACEUTICAL FORM AND CONTENTS Solution for injection in pre-filled syringe 1 pre-filled syringe with automatic needle guard (0.6 ml).
Ena napolnjena injekcijska brizga z avtomatičnim ščitnikom igle (0,6 ml).
Injection site reactions, including injection site erythaema (uncommon) as well as injection site pain (common events) have occurred on initial or subsequent treatment with pegfilgrastim.
Med začetnim ali nadaljnjim zdravljenjem s pegfilgrastimom so se pojavile reakcije na mestu injiciranja, vključno z eritemom na mestu injiciranja (občasno) in tudi bolečino na mestu injiciranja (pogosto).
Pulmonary adverse events
Neželeni dogodki na pljučih
In a placebo-controlled, double blind study in patients with breast cancer the effect of pegfilgrastim on the incidence of febrile neutropenia was evaluated following administration of a chemotherapy regimen associated with a febrile neutropenia rate of 10-20 % (docetaxel 100 mg/m2 every 3 weeks for 4 cycles).
V dvojno slepi, s placebom kontrolirani študiji pri bolnicah z rakom na dojki so ocenili učinek pegfilgrastima na pojav febrilne nevtropenije po uporabi takšne sheme kemoterapije, ki je povezana z 10
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BLISTERED SYRINGE LABEL
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
White blood cell (WBC) counts of 100 x 109/L or greater have been observed in less than 1 % of patients receiving pegfilgrastim.
Pri manj kot 1 % bolnikov, ki dobivajo pegfilgrastim, so opazili število belih krvničk, ki je enako 100 × 109/l ali višje.
Common side effects (may affect up to 1 in 10 people)
Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 oseb):
Hypersensitivity reactions;
Bolezni imunskega sistema preobčutljivostne reakcije; anafilaksija
APPROPRIATE
Pomembno
Vascular Disorders
kožni vaskulitis
Each pre-filled syringe contains 6 mg of pegfilgrastim in 0.6 ml of solution for injection.
Ena napolnjena injekcijska brizga vsebuje 6 mg pegfilgrastima v 0,6 ml raztopine za injiciranje.
Caution: Avoid contact with the plunger and needle during the preparation of the syringe, The safety device is normally activated by pressure from the plunger on the syringe.
Varnostna naprava se običajno aktivira s pritiskom bata na brizgo.
Vertrieb
Sledljivost
Inspect the medicine content through the viewing window of the pre-filled syringe.
S pomočjo pregledovalnega okenca na napolnjeni injekcijski brizgi preglejte zdravilo.
Talk to your doctor, pharmacist or nurse before using Grasustek:
Opozorila in previdnostni ukrepi Pred začetkom uporabe zdravila Grasustek se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro:
The safety and efficacy of Grasustek have not been evaluated in patients receiving chemotherapy associated with delayed myelosuppression e.g., nitrosoureas.
Pri bolnikih, ki prejemajo kemoterapijo, povezano z odloženo mielosupresijo, na primer nitrozouree,
Capillary leak syndrome1
Bolezni živčevja glavobol1 Žilne bolezni sindrom kapilarne prepustnosti aortitis
After the injection is complete, one of the below alternatives can be followed : -Remove the needle from the injection site and release the plunger until the entire needle is covered by the guard.
- Odstranite iglo z mesta injiciranja in sprostite bat, tako da varnostni ščitnik prekriva celotno iglo.
Each pre-filled syringe contains 6 mg of pegfilgrastim in 0.6 ml of solution.
Ena napolnjena injekcijska igla vsebuje 6 mg pegfilgrastima v 0,6 ml raztopine.
România
Bucharest, Romania
Immune system Disorders
Organski sistem po MedDRA Neželeni učinki
How to store Grasustek
Shranjevanje zdravila Grasustek
Shelf life
USV Private Limited
Injection site pain Non-cardiac chest pain
bolečina v prsih, ki ne izvira iz srca reakcije na mestu injiciranja
PHARMACEUTICAL FORM Solution for injection.
raztopina za injiciranje v napolnjeni injekcijski brizgi
Keep pre-filled syringes out of the sight and reach of children.
Napolnjene injekcijske brizge shranjujte nedosegljive otrokom.
This summary was last updated in May 2013.
Ta povzetek je bil nazadnje posodobljen 05-2013.
The authorisation was renewed on 29 January 2006.
Dovoljenje za promet z zdravilom je bilo podaljšano dne 29. januarja 2006.
Other information about Pirsue:
Druge informacije o zdravilu Pirsue:
The clinical effectiveness was studied in a large number of dairy herds in 8 European countries.
Klinično učinkovitost so preučili na velikem številu čred molznih krav v 8 evropskih državah.
The European Commission granted a marketing authorisation valid throughout the European Union, for Pirsue on 29 January 2001.
Evropska komisija je dovoljenje za promet z zdravilom Pirsue, veljavno po vsej Evropski uniji, odobrila dne 29. januarja 2001.
Information was provided on the pharmaceutical quality, the tolerance of the product in cows and the safety in humans (people in contact with the product and consumers of meat and milk) and the environment.
Predloženi so bili podatki o farmacevtski kakovosti, toleranci na zdravilo pri kravah ter njegovi varnosti za ljudi (za ljudi, ki pridejo v stik z zdravilom, in ljudi, ki uživajo meso in mleko) in okolje.
Pirlimycin hydrochloride
Pirlimicin hidroklorid
As a result, the bacteria cannot produce any more protein and will stop growing.
Zaradi tega bakterije ne morejo več tvoriti beljakovin in posledično se njihova rast prekine.
Cows with subclinically infected udders were treated with Pirsue (once daily for 8 days) or with another antibiotic, authorised in the EU to treat these infections.
Krave s subklinično okužbo vimena so zdravili z zdravilom Pirsue (enkrat dnevno v trajanju 8 dni) ali z drugim antibiotikom, ki je dovoljen v EU za zdravljenje teh okužb.
Subclinical means that the infection is present but not sufficiently developed to produce clear clinical signs in the cow.
Subklinična okužba pomeni, da je okužba že prisotna, vendar se še ni dovolj razvila, da bi se pri kravi pokazali jasni klinični znaki.
Mastitis is an infection in the udder.
Mastitis je okužba vimena.
What is the risk associated with Pirsue?
Kakšna tveganja so povezana z zdravilom Pirsue?
Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
Njegov namen je pojasniti, kako je Odbor za zdravila za uporabo v veterinarski medicini (CVMP) ocenil predloženo dokumentacijo, na podlagi česar je oblikoval priporočila glede uporabe zdravila.
Information on the prescription status of this product may be found on the label/outer package.
Informacije o predpisovanju tega zdravila lahko najdete na notranji/zunanji ovojnini.
The benefit-risk balance may be found in module 6 of this EPAR.
Razmerje med koristmi in tveganji je na voljo v modulu 6 tega Evropskega javnega poročila o oceni zdravila (EPAR).
Since milk is routinely checked for bacteria and other signs of infection, early stages of an udder infection in a dairy cow can easily be diagnosed.
Ker se mleko redno preverja za vsebnost bakterij in druge znake okužbe, lahko pri molznih kravah z lahkoto odkrijemo zgodnje stopnje okužbe vimena.
What benefit has Pirsue shown during the studies?
Kakšne koristi je zdravilo Pirsue izkazalo med raziskavami?
These infections were caused by incorrect administration of the product by the operator who, by inserting the syringe without adequate cleansing procedures, also inserted pathogenic (disease causing) bacteria from the environment into the udder.
Te okužbe so bile posledice nepravilnega dajanja zdravila, pri čemer je oseba, ki je dajala zdravilo, vstavila brizgo brez primernega postopka čiščenja, zato je iz okolja v vime prenesla patogene bakterije (povzročitelje bolezni).
Milk samples were checked daily up to 30 days after treatment for bacteria and for other signs of infection.
Vzorce mleka so vsak dan do 30. dne po končanem zdravljenju preverjali za vsebnost bakterij in druge znake okužbe.
Pirsue is generally well tolerated in cows.
Krave na splošno dobro prenašajo zdravilo Pirsue.
Pirsue is given into each infected teat of the udder for 8 consecutive days.
Zdravilo Pirsue dajemo v vsak okužen sesek 8 dni zapored.
What is the time to allow before the animal can be slaughtered and the meat used for human consumption (withdrawal period)?
Koliko časa mora preteči, preden se žival lahko zakolje in meso porabi za prehrano ljudi (obdobje karence)?
However, in rare cases, serious bacterial udder infections have occurred after treatment.
Vendar so se v nekaterih redkih primerih po zdravljenju pojavile hude bakterijske okužbe vimena.
What is the time to allow before milk can be taken from the animal for human consumption?
Koliko časa mora preteči, preden se lahko mleko uporabi za prehrano ljudi?
Why has Pirsue been approved?
Zakaj je bilo zdravilo Pirsue odobreno?
In these studies, the effective concentration of pirlimycin required to stop bacterial growth was established.
V teh raziskavah so določili učinkovito koncentracijo pirlimicina, ki je potrebna za zaustavitev rasti bakterij.
Pirsue is used in dairy cows to treat subclinical mastitis caused by specific groups of bacteria.
Zdravilo Pirsue se uporablja za zdravljenje subkliničnega mastitisa pri molznih kravah, ki ga povzročajo posebne skupine bakterij.
It works by blocking the bacteria's ribosomes; this is the part of the cell where proteins are produced.
Deluje tako, da blokira delovanje bakterijskih ribosomov, ki v celicah tvorijo beljakovine.
The field trial showed that treatment with Pirsue at the recommended dose was effective in the treatment of subclinical udder infections.
Preskušanje na terenu je pokazalo, da je zdravljenje s priporočenim odmerkom zdravila Pirsue učinkovito pri zdravljenju subkliničnih okužb vimena.
Pirlimycin hydrochloride can cause severe eye and skin irritation.
Pirlimicin hidroklorid močno draži oči in kožo.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Pirsue exceed the risks for the treatment of subclinical mastitis in lactating cows and recommended that Pirsue be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je mnenja, da so koristni učinki zdravila Pirsue za zdravljenje subkliničnega mastitisa pri kravah v obdobju laktacije večji od z njim povezanih tveganj, zato priporoča odobritev dovoljenja za promet z zdravilom Pirsue.
Special care must, therefore, be taken by the operator not to introduce pathogens into the teat.
To pomeni, da mora oseba, ki je daje zdravilo, biti posebno pozorna, da v sesek ne vnese patogenih organizmov.
The active substance in Pirsue is pirlimycin hydrochloride, an antibiotic of the lincosamide group.
Zdravilna učinkovina zdravila Pirsue je pirlimicin hidroklorid, ki je antibiotik iz skupine linkozamidov.
What is Pirsue used for?
Za kaj se zdravilo Pirsue uporablja?
It is given to dairy cows by infusion into the udder via the teat canal using a pre-filled syringe.
Daje se molznim kravam v vime preko seskovega kanala z infuzijo s pomočjo napolnjene brizge.
How has Pirsue been studied?
Kako je bilo zdravilo Pirsue raziskano?
The antimicrobial effectiveness of pirlimycin against different groups of bacteria causing disease in dairy cows was investigated in microbiological laboratories.
V mikrobioloških laboratorijih so raziskali učinkovitost protimikrobnega delovanja pirlimicina proti različnim skupinam bakterij, ki povzročajo bolezen pri molznih kravah.
The results of these studies showed that Pirsue is effective at inhibiting the bacterial growth of a range of bacteria.
Rezultati teh raziskav so pokazali, da zdravilo Pirsue učinkovito zavira rast določenih bakterij.
Pirsue is an antibiotic that contains pirlimycin hydrochloride as the active substance.
Zdravilo Pirsue je antibiotik, ki vsebuje zdravilno učinkovino pirlimicin hidroklorid.
How does Pirsue work?
Kako zdravilo Pirsue deluje?
Both, the teat and the udder should be adequately cleansed and the teat end disinfected before using Pirsue.
Pred uporabo zdravila Pirsue je treba sesek in vime primerno očistiti, konec seska pa razkužiti.
Skin that has been in contact with Pirsue should be washed and eyes should be flushed with water for 15 minutes immediately after exposure.
Oči je treba takoj po stiku z raztopino začeti spirati z vodo in nadaljevati s tem 15 minut.
What is Pirsue?
Kaj je zdravilo Pirsue?
After the last day of treatment with Pirsue, treated cows should not be slaughtered for 23 days.
Zdravljena krava se ne sme zaklati 23 dni po zadnjem dnevu zdravljenja z zdravilom Pirsue.